Navigation Links
NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007
Date:10/25/2007

BEDMINSTER, N.J., Oct. 25 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will report its third quarter financial results and Nycomed's decision whether to proceed with ex-U.S. development and commercialization of GATTEX(TM) (teduglutide) on Thursday, November 1, 2007. NPS expects to receive notification from Nycomed at the end of this month regarding Nycomed's plans to partner with NPS on the development of GATTEX(TM) (teduglutide) outside North America. The announcement will be followed by a conference call and webcast at 5:00 p.m. EDT, featuring Dr. Anthony Coles, president and CEO, and other members of the NPS executive team.

To participate in the conference call, dial (866) 770-7051 and use passcode 53288322. International callers may dial (617) 213-8064, using the same passcode. In addition, live audio of the conference call will be simultaneously broadcast over the Internet and may be accessed on the company's web site (http://www.npsp.com).

If you are unable to participate in the live call, a replay will be available at (888) 286-8010, with passcode 16038876, until midnight EST, November 15, 2007. International callers may access the replay by dialing (617) 801-6888, using the same passcode. The webcast will also be available on the NPS website for the same period of time.

About NPS Pharmaceuticals

NPS Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. The company has drug candidates in various stages of
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
4. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
5. Signal Transduction Reporting Systems Using Cis-Acting Enhancer Elements
6. Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion Transactivators
7. Versatile Reporter Vectors for Monitoring Viral Transduction
8. In Vivo Signal Transduction Pathway Reporting Systems
9. Improved Vectors for PathDetect Trans-Reporting Systems
10. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
11. Cis-Reporting System Monitors Intracellular Calcium Mobilization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Audubon, PA and London (PRWEB) November 21, 2014 ... in December will explore what comes next for ALS research ... clinical sites. , After the Ice Bucket Challenge: Where ... Merit Cudkowicz, Date: Tuesday, 2 December 2014, Time: ... complimentary , Join expert speaker Dr. Merit Cudkowicz, Julianne ...
(Date:11/22/2014)... During his lifetime Richard L. Sharp ... surround himself with great people and take risks to ... often marveled at his extraordinarily courageous attitude when taking ... -- even with his death impending—that’s how he continued ... would ultimately take his life. , Carrying on Sharp’s ...
(Date:11/22/2014)... MA (PRWEB) November 21, 2014 ... key investors will gather on December 3rd at ... Biotech Conferences series. GeneticRx will take place at ... Medical School and will discuss the present and ... therapy, exon skipping, and gene editing—as well as ...
(Date:11/22/2014)... CannLabs, Inc. (OTCQB: CANL), the leading ... methodologies relating to cannabis, today announced that it has ... from an existing stockholder of the Company. , ... from one of our existing stockholders,” stated Mark ... help accelerate our planned expansions into the Connecticut and ...
Breaking Biology Technology:DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2CannLabs Secures $750,000 Line Of Credit 2
... Nov. 27 Nastech,Pharmaceutical Company Inc. (Nasdaq: NSTK ... Capital Markets Focus on Healthcare Conference on,Wednesday, December 5, ... Hotel in New York City., To access the ... to,Nastech,s website at http://www.nastech.com approximately 15 minutes ...
... FDA 510(k) (Pre-Market Notification), Pathway for AppyScore(TM), the First Blood-based Screening ... ... Colo., Nov. 27 AspenBio Pharma,Inc. (Nasdaq: APPY ) an ... for animals and humans, has,received an official response from the Food ...
... - Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) ("Oncolytics") ... 7,300,650 entitled "Reovirus for the Treatment of Neoplasia.",The ... treat cancers that,have inactivated PKR, whether the PKR ... factors. PKR is a host cellular protein responsible ...
Cached Biology Technology:AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 2AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 3AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 4Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent 2
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
(Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... CLEVELAND/ORLANDO University Hospitals Case Medical Center researchers ... a second chancejust not as they originally thought. ... harnessed from bone marrow that were believed to have ... if injected into the heart within two weeks of ...
... step closer to understanding what drives tumor metastasis, as ... can slow their own growth. In a recent ... the American Association for Cancer Research, Ral A. Ruggiero, ... medicine at the National Academy of Medicine in Buenos ...
... Findings from preclinical studies in a skin ... alone, or first-generation BRAF inhibitors used in combination ... have the potential to prevent drug-induced skin lesions ... The studies, presented at the AACR-NCI-EORTC International ...
Cached Biology News:Post heart attack recovery may not be aided by stem cell injections, but trial demonstrates promise 2New approaches may prevent certain side effects in BRAF mutation-positive melanoma 2
Kit Components: Anti-Acetylated Histone H3 Salmon Sperm DNA/Protein A Agarose All necessary buffers. ...
Liquid. 50 μg/ml in PBS, pH 7.4. PROTECT FROM LIGHT. A convenient form of propidium iodide useful for flow cytometry studies. RTECS SF7949600, CAS 25535-16-4, M.W. 668.4. ...
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... ChipWriter Pro systems are high-precision microarrayers ... other biological samples. VersArray ChipWriter Pro ... spot density, and reproducibility to deliver ... of substrates. Their modular component design ...
Biology Products: